Xencor XNCR 深 滬
等待開盤 09-06 09:30:00 美东时间
8.55
+0.180
+2.15%
華盛通- 最 高8.84
- 今 開8.46
- 成交量 66.52万股
- 最 低 8.40
- 昨 收 8.37
- 總市值 6.10亿
- 52周最高 27.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.92
- 委 比 -0.87%
- 總股本 7132.30万
- 歷史最高 58.345
- 量 比 0.90
- 振 幅 5.26%
- 歷史最低 5.75
- 每 手 1
- 風險率 6.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多二代IO争霸，暗藏哪些玄机？
（来源：药剂Talks） 下一代肿瘤“药王”，极有可能诞生于PD-(L)1 Plus领域。 以K药为代表的PD-1单抗，开启了一代IO（肿瘤免疫治疗）时代，但...
09-04 07:52
Beyond The Numbers: 4 Analysts Discuss Xencor Stock
Ratings for Xencor (NASDAQ:XNCR) were provided by 4 analysts in the past three ...
09-03 05:00
Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target
Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.
09-02 23:20
RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $15
RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $32 to $15.
08-21 22:17
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
Wedbush Maintains Outperform on Xencor, Lowers Price Target to $26
Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $31 to $26.
08-07 20:39
Xencor Q2 EPS $(0.41) Beats $(0.72) Estimate, Sales $43.61M Beat $21.45M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.72) by 43.06 percent. This is a 61.68 percent increase over losses of $(1.07) per share from the same
08-07 04:43
Avacta Appoints Dr. David Liebowitz as Chief Medical Officer to Lead Cancer Drug Strategy
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii
07-01 19:04
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Polyrizon (NASDAQ:PLRZ) stock moved upwards by 57.1% to $0.58 during F...
05-10 05:06
